Live feed07:05:00·1186dPRReleasevia QuantisnowuniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1ByQuantisnow·Wall Street's wire, on your screen.QURE· uniQure N.V.Health Care
